Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.76 USD | -0.92% | +14.13% | -57.28% |
04-26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
04-12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.28% | 395M | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-17.57% | 31.47B | |
+54.44% | 25.24B | |
-12.79% | 15.82B | |
-9.12% | 11.96B | |
-15.34% | 11.89B | |
-42.56% | 11.61B | |
+4.87% | 8.84B |
- Stock Market
- Equities
- RVNC Stock
- News Revance Therapeutics, Inc.
- Barclays Adjusts Revance Therapeutics' Price Target to $22 From $33, Maintains Overweight Rating